Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Sales

EOS Imaging Reports Strong Revenue Growth for Half Year 2020


Regulatory News:

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces preliminary consolidated revenues for the half year ending June 30, 2020.

SECOND QUARTER & FIRST SEMESTER 2020 HIGHLIGHTS

Mike Lobinsky, CEO of EOS imaging, comments: "The first half of 2020 was marked by the COVID-19 outbreak which has temporarily impacted the Company's momentum. Nevertheless, we are pleased with the restart of system installations in Q2 and the strong interest and adoption of our new EOSedge system which represents 86% of half-yearly orders in the countries where it is registered. The growth in maintenance revenues fuels our recurring business which we continue to develop. Finally, our global sales pipeline continued to grow and mature in the first half of 2020 with benefits expected in quarters to come. We remain bullish on EOS being well positioned to accelerate growth once the health crisis recedes."

Equipment orders

Unaudited / including forex impact3 / ?m

As of June 30

Q2 2020

Q2 2019

 

H1 2020

H1 2019

Equipment orders received (over the period)

2.00

6.57

 

4.97

12.82

Equipment order book (end of period)

13.69

12.05

 

13.69

12.05

Revenues

Unaudited / including forex impact / ?m

As of June 30

Q2 2020

Q2 2019

 

H1 2020

H1 2019

Equipment

4.09

0.72

 

4.81

0.77

Maintenance

3.04

2.45

 

5.76

4.66

Consumables and associated services

0.14

0.26

 

0.47

0.57

Total revenues

7.27

3.42

 

11.04

6.00

Revenues

Unaudited / including forex impact / ?m

As of June 30

Q2 2020

Q2 2019

 

H1 2020

H1 2019

EMEA

2.09

1.66

 

3.81

2.92

APAC

1.39

0.18

 

2.04

0.35

NAM

3.77

1.58

 

5.17

2.74

LATAM

0.01

0.00

 

0.02

0.00

Total revenues

7.27

3.42

 

11.04

6.00

As of end-June 2020, EOS imaging's cash position amounted ?9.9 million4, compared to ?8.2 million at 31 December 2019. The increase in cash was driven by recurring maintenance revenues, the re-start of the installation activity following the lock-down, government support programs and cost reduction measures implemented by EOS management.

As it did for many companies, the COVID pandemic impacted EOS in the first half of 2020. During this time, the EOS management team continued to monitor the situation and made timely decisions to ensure the safety of the company's employees and customers while continuing to meet the needs of hospitals and caregivers. EOS implemented a cost management plan in H1, which has extended into H2, effectively lowering expenses and contributing to the improved cash position at the end of Q2. The company has also benefitted from Government programs designed to provide support during the pandemic.

EOS Global Sales and Marketing teams remain active conducting remote customer demos and virtual tradeshows which continued to build the sales pipeline. The company started to see some markets open up in late Q2 and remains optimistic about recovery once the situation has normalized.

Next financial press release: 2020 first-half results, on September 23, 2020

ABOUT EOS imaging

EOS imaging is a global medical device company that designs, develops and markets innovative, low dose 2D/3D full body and weight-bearing imaging, rapid 3D modeling of EOS patient X-ray images, web-based patient-specific surgical planning, and integration of surgical plan into the operating room that collectively bridge the entire spectrum of care from imaging to post-operative assessment capabilities for orthopedic surgery. With a primary focus on hips, knees, and spine, EOS imaging is targeting a $2 billion annual market opportunity. EOS imaging has over 350 system installations in more than 30 countries generating more than 1 million patient exams annually. EOS imaging has corporate locations in U.S., France, Canada, Germany, and Singapore, and has more than 165 employees. For additional information, please visit www.eos-imaging.com.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 - Ticker: EOSI

1 In order to better meet customer expectations and improve its working capital, EOS imaging made a change in its commercial cycle at the beginning of 2019 by organizing the delivery of EOS® systems at the start of the installation phase, and no longer just after receiving the equipment order. Therefore, (i) new received orders build an order book and (ii) sales are recorded according to the pace of delivery of the EOS® systems. As installations usually take place 3 to 12 months after the order, a similar lag occurs on deliveries. While 2019 equipment revenues were temporarily impacted by the transition phase, this evolution leads to improvements in production and logistics management and helps reduce working capital requirements.
2 Roye, B.D., Simhon, M.E., Matsumoto, H. et al. Establishing consensus on the best practice guidelines for the use of bracing in adolescent idiopathic scoliosis. Spine Deform (2020). https://doi.org/10.1007/s43390-020-00060-1
3 including forex impact of 0.05m?
4 Un-audited figures


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: